[ad_1]
Scientists say that blood taken from a young person can be the key to maintaining good long-term health.
The blood factors obtained in young people can improve the health of animals at the end of life, revealed the study published in the journal Nature.
This could also help reduce the risk of developing age-related diseases, said scientists at University College London (UCL).
Lady Linda Partridge, a geneticist at UCL, said research shows that young bloods could allow humans to live without diseases, such as cancer and heart disease, until their deaths.
"I would say that aging is the emperor of all diseases," she told The Times.
"Many people view aging as" natural "and therefore you should not interfere with nature, but we have always considered it an ethical imperative to cure the disease where we find it."
The analysis of Professor Partridge's data forms is part of a wave of studies and essays backed by Peter Thiel, co-founder of PayPal, in a San Francisco start-up called Ambrosia.
Study shows that blood factors in young people can improve the health of animals at the end of their life
The trials saw elderly people injected with young blood, which would cost about $ 8,000 (6,200 pounds) if made available to the public.
Professor Partridge's study showed that older mice do not develop age-related diseases after receiving young blood.
The mice also maintained a strong cognitive function, while the younger ones who received older blood experienced the opposite effect and became ill.
"The convenient accessibility of the human microbiome and blood system makes therapeutic manipulation particularly attractive, but animal research is needed to establish long-term consequences and possible side effects," the study said.
"Blood is the most accessible tissue and therefore the most studied, but it is much less used in animal studies."
The trials conducted by American start-up Ambrosia involved 70 participants – all involved aged at least 35 years old.
After receiving plasma – the main component of the blood – volunteers aged 16 and 25, researchers noted improvements in biomarkers for various diseases.
Ambrosia currently offers teenage blood plasma at a cost of $ 8,000 (6,200 pounds) for two and a half liters.
Meanwhile, another startup called Elevian thinks that a blood protein called GDF11 is the key ingredient.
The company announced this week having an investment of 5.5 million dollars (4.2 million pounds sterling) to support its approach.
Source link
